Arbutus Biopharma Corp Deferred Revenue
Arbutus Biopharma Corp (ABUS) had Deferred Revenue of $0 as of 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-03-23
- 2013-12-31: Deferred Revenue, Current 3.46M CAD.
- 2012-12-31: Deferred Revenue, Current 3.14M CAD; Deferred Revenue, Current as first filed 3.13M CAD.
- 2011-12-31: Deferred Revenue, Current 2.81M CAD.
- 2010-12-31: Deferred Revenue, Current 1.98M CAD.
CAD
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2013-12-31 | 3.46M CAD 10-K · filed 2014-03-28 | |
| 2012-12-31 | 3.14M CAD 10-K · filed 2014-03-28 | 3.13M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 2.81M CAD 20-F · filed 2013-03-27 | |
| 2010-12-31 | 1.98M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Deferred Revenue, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-03-31 | $6.76M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $7.57M 10-K · filed 2026-03-23 |
| 2024-09-30 | $10.91M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $11.03M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $11.55M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $11.79M 10-K · filed 2025-03-27 |
| 2023-09-30 | $12.11M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $15.33M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $15.05M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $16.46M 10-K · filed 2024-03-05 |
| 2022-09-30 | $14.88M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $16.97M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $23.25M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-02 |
| 2018-03-31 | $1.72M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $2.74M 10-Q · filed 2018-05-04 |
| 2017-09-30 | $15.00K 10-Q · filed 2017-11-02 |
| 2017-06-30 | $2.62M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $2.62M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $15.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $15.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $711.00K 10-Q · filed 2016-08-04 |
| 2016-03-31 | $924.00K 10-Q · filed 2016-05-04 |
| 2015-12-31 | $868.00K 10-K · filed 2017-03-22 |
| 2015-09-30 | $4.83M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $5.61M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $5.23M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $5.78M 10-K · filed 2016-03-09 |
| 2014-09-30 | $4.88M 10-Q · filed 2014-11-07 |
| 2014-06-30 | $6.04M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $5.62M 10-Q · filed 2014-05-14 |
| 2013-12-31 | $3.46M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |